PeptideLabs Logo
PeptideLabs
Quality Documentation
Back to all 64 profiles
Clinical researchIn clinical research

Community protocol · VIP

VIP: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: Vasoactive intestinal peptide · Aviptadil

Sources checked: 27 August 2026

Important safety and liability notice

This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

VIP

Influences vascular, intestinal, pulmonary and neural signalling. Therapeutic uses and analogues remain under clinical study.

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Amounts, timing and cycles

Clinical research

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Amount status

Trials use protocol-bound amounts and escalation; this does not create a safe community dose.

Profile evidence level: clinical.

Timing

Timing is set by each trial protocol and may differ substantially between studies.

No individual recommendation.

Cycle/duration

Duration is study-specific and ends according to protocol; long-term safety may remain unknown.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitution and U-100 conversion

Reconstitution calculator

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Reconstitution calculator

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Endogenous neuropeptide acting at VPAC receptors

VIP is classified as “Endogenous neuropeptide acting at VPAC receptors”. Influences vascular, intestinal, pulmonary and neural signalling. Therapeutic uses and analogues remain under clinical study. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

VPAC receptor signalling

This studies how binding to VPAC receptors mediates effects on blood vessels, digestion, and immune function, similar to a signal reaching several organ systems at once. Blood flow and inflammation markers are measured in lab and clinical models.

02

Vascular, lung, and gut signalling

This examines how a signal affects blood vessels, airway tissue, and the digestive tract at the same time, similar to one dispatcher relaying instructions to several different departments at once. Researchers typically measure blood flow, airway function, and gut activity in laboratory or clinical models.

03

Neuroendocrine signalling

This examines how the nervous system and hormone-producing glands communicate with each other, similar to a two-way phone line connecting the brain to distant organs. Researchers typically measure hormone levels in blood alongside markers of nervous system activity.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Biohacker and longevity forums

Users compare self-assembled combinations of peptides aimed at influencing ageing processes or energy levels, often based on blood tests or subjective wellbeing scales. Personal self-experiments and marketing promises do not replace controlled long-term human studies.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and risk boundaries

  • Reproductive, vasoactive or fluid-regulating signals can affect hormone axes, blood pressure, heart rate, fluid balance and pregnancy; risks depend strongly on route and indication.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Pregnancy or fertility planning, cardiovascular disease, electrolyte/fluid disorders and hormone-sensitive disease require indication-specific medical oversight.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on the objective, vital signs, fluid balance, electrolytes, reproductive hormones and clearly defined clinical endpoints may be monitored.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

In clinical trials

Therapeutic uses and analogues remain under clinical study, without broad approval.

Published evidence

The substance is currently being studied in structured human clinical trials, but a general approval does not yet exist.

VIP acts through VPAC receptors on vascular, intestinal and pulmonary signalling, unlike oxytocin, which primarily governs reproductive pathways.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

In clinical research

A clinical-development candidate, not an approved medicinal product.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile